|
University of California, San Francisco |
Linda Giudice |
SEED Grant |
Human Embryonic Stem Cell Differentiation to Trophoblast: Basic Biology and Clinical Translation to Improve Human Fertility |
$640,399 |
|
University of California, San Francisco |
Su Guo |
SEED Grant |
Identifying small molecules that stimulate the differentiation of hESCs into dopamine-producing neurons |
$564,309 |
|
University of Southern California |
David Hinton |
SEED Grant |
Therapeutic potential of Retinal Pigment Epithelial cell lines derived from hES cells for retinal degeneration. |
$684,322 |
|
University of California, Irvine |
Michelle Khine |
SEED Grant |
Micro Platform for Controlled Cardiac Myocyte Differentiation |
$363,707 |
|
University of Southern California |
Wange Lu |
SEED Grant |
Regulation of human neural progenitor cell proliferation by Ryk-mediated Wnt signaling |
$668,987 |
|
Children's Hospital of Los Angeles |
Elizabeth Lawlor |
SEED Grant |
hESC as tools to investigate the neural crest origin of Ewing's sarcoma |
$675,001 |
|
University of California, Santa Cruz |
David Feldheim |
SEED Grant |
Assessing the role of Eph/ephrin signaling in hESC growth and differentiation |
$499,999 |
|
University of California, San Diego |
Sylvia Evans |
SEED Grant |
Specification of Ventricular Myocyte and Pacemaker Lineages Utilizing Human Embryonic Stem Cells |
$609,999 |
|
University of California, Los Angeles |
William Lowry |
SEED Grant |
Modeling Human Embryonic Development with Human Embryonic Stem Cells |
$571,575 |
|
Sanford-Burnham Medical Research Institute |
Ziwei Huang |
SEED Grant |
New Chemokine-Derived Therapeutics Targeting Stem Cell Migration |
$759,000 |
|
University of California, Los Angeles |
Siavash Kurdistani |
SEED Grant |
Cellular epigenetic diversity as a blueprint for defining the identity and functional potential of human embryonic stem cells |
$641,047 |
|
University of California, San Diego |
Catriona Jamieson |
SEED Grant |
Derivation and Characterization of Cancer Stem Cells from Human ES Cells |
$642,500 |
|
Stanford University |
Krishna Shenoy |
SEED Grant |
Technology for hESC-Derived Cardiomyocyte Differentiation and Optimization of Graft-Host Integration in Adult Myocardium |
$634,287 |
|
Stanford University |
Mark Kay |
SEED Grant |
Novel vectors for gene transfer into human ES cells |
$640,642 |
|
Stanford University |
Calvin Kuo |
SEED Grant |
Differentiation of Human Embryonic Stem Cells to Intestinal Fates |
$578,943 |
|
The J. David Gladstone Institutes |
Warner Greene |
SEED Grant |
The APOBEC3 Gene Family as Guardians of Genome Stability in Human Embryonic Stem Cells |
$777,467 |
|
University of California, Los Angeles |
Zoran Galic |
SEED Grant |
Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells |
$642,501 |
|
University of California, San Diego |
Anirvan Ghosh |
SEED Grant |
Generation of forebrain neurons from human embryonic stem cells |
$612,075 |
|
University of California, Santa Cruz |
Bin Chen |
SEED Grant |
In vitro differentiation of hESCs into corticospinal motor neurons |
$500,000 |
|
Sanford-Burnham Medical Research Institute |
Huei-sheng Chen |
SEED Grant |
Development of Neuro-Coupled Human Embryonic Stem Cell-Derived Cardiac Pacemaker Cells. |
$744,639 |
|
Stanford University |
John Cooke |
SEED Grant |
EC regeneration in cerebrovascular ischemia: role of NO |
$658,125 |
|
University of California, San Diego |
Shu Chien |
SEED Grant |
Combinatorial Platform for Optimizing Microenvironments to Control hESC Fate |
$638,140 |
|
The Salk Institute for Biological Studies |
Senyon Choe |
SEED Grant |
A method to maintain and propagate pluripotent human ES cells |
$796,348 |
|
Sanford-Burnham Medical Research Institute |
Gregg Duester |
SEED Grant |
Retinoic Acid-FGF Antagonism during Motor Neuron Differentiation of Human ES Cells |
$759,000 |
|
University of California, Los Angeles |
Irvin Chen |
SEED Grant |
Genetic modification of the human genome to resist HIV-1 infection and/or disease progression |
$642,652 |
|
University of California, San Francisco |
Robert Blelloch |
SEED Grant |
MicroRNA Regulation of Human Embryonic Stem Cell Self-Renewal and Differentiation |
$631,831 |
|
Buck Institute for Age Research |
Dale Bredesen |
SEED Grant |
Programmed Cell Death Pathways Activated in Embryonic Stem Cells |
$734,202 |
|
Human BioMolecular Research Institute |
John Cashman |
SEED Grant |
Discovering Potent Molecules with Human ESCs to Treat Heart Disease |
$714,654 |
|
University of California, San Diego |
Karl Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,376,802 |
|
University of California, Los Angeles |
Robb Maclellan |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$1,378,076 |
|
University of California, Davis |
Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$1,052,715 |
|
University of Southern California |
Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,468,360 |
|
University of California, Los Angeles |
Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
|
University of California, Los Angeles |
Bennett Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,363,262 |
|
University of Southern California |
Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,440,822 |
|
University of California, Los Angeles |
Michael Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
|
Stanford University |
Susan McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,407,076 |
|
University of California, San Diego |
Eugene Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,376,802 |
|
Stanford University |
Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,436,185 |
|
Stanford University |
Helen Blau |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,414,841 |
|
Western University of Health Sciences |
Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer's Disease |
$2,120,833 |
|
The J. David Gladstone Institutes |
Sheng Ding |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$2,943,375 |
|
University of California, Santa Cruz |
Camilla Forsberg |
New Faculty I |
Mechanisms of Stem Cell Fate Decisions |
$2,330,111 |
|
University of California, Berkeley |
Irina Conboy |
New Faculty I |
Identification of hESC-mediated molecular mechanism that positively regulates the regenerative capacity of post-natal tissues |
$2,246,020 |
|
University of California, Irvine |
Frank LaFerla |
Early Translational I |
Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease |
$3,599,997 |
|
University of California, San Diego |
Yang Xu |
Early Translational I |
Developing induced pluripotent stem cells into human therapeutics and disease models |
$5,165,028 |
|
Scripps Research Institute |
Jeanne Loring |
Early Translational I |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$6,292,290 |
|
Stanford University |
Anne Brunet |
New Faculty I |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,520 |
|
Stanford University |
Michael Longaker |
Early Translational I |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$5,767,050 |
|
University of California, Los Angeles |
Gabriel Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,503,069 |
|
Children's Hospital of Los Angeles |
Donald Kohn |
Disease Team Planning |
STEM CELL GENE THERAPY FOR SICKLE CELL DISEASE |
$33,110 |
|
University of Southern California |
Andrew McMahon |
Research Leadership 10 |
Repair and regeneration of the nephron |
$5,672,206 |
|
University of California, Irvine |
Michael Drake |
Major Facilities |
No Title |
$27,156,000 |
|
Sanford-Burnham Medical Research Institute |
Mark Mercola |
Disease Team Planning |
"Stem Cell Therapies for Heart Failure" |
$53,150 |
|
University of California, Los Angeles |
Gene Block |
Major Facilities |
No Title |
$19,854,900 |
|
Beckman Research Institute of City of Hope |
Michael Barish |
Disease Team Planning |
Genetically-modified neural stem cells for treatment of high-grade glioma |
$55,000 |
|
University of California, Merced |
John White |
Major Facilities |
No Title |
$4,359,480 |
|
University of California, San Diego |
Dennis Carson |
Disease Team Planning |
CIRM Planning Grant in Leukemia |
$55,000 |
|
University of California, Santa Barbara |
Glenn Lucas |
Major Facilities |
No Title |
$3,205,800 |
|
Stanford University |
Robert Robbins |
Disease Team Planning |
{REDACTED} Cardiovascular Regenerative Team |
$55,000 |
|
University of California, Santa Cruz |
Margaret Delaney |
Major Facilities |
No Title |
$7,191,950 |
|
University of California, Los Angeles |
Stanley Carmichael |
Disease Team Planning |
Development of a Stem Cell Therapy to Promote Functional Recovery in Stroke |
$44,792 |
|
University of California, San Francisco |
Jeffrey Bluestone |
Disease Team Planning |
A CIRM Disease Team for the Treatment and Cure of Diabetes |
$55,000 |
|
University of California, San Francisco |
A. Washington |
Major Facilities |
No Title |
$34,862,400 |
|
University of Southern California |
David Woodley |
Disease Team Planning |
Clinical Regenerative Wound Healing With Stem Cells |
$42,574 |
|
University of Southern California |
Chrysostomos Nikias |
Major Facilities |
No Title |
$26,972,500 |
|
University of California, San Francisco |
Jeffrey Lotz |
Disease Team Planning |
A CIRM Disease Team for the Repair of Traumatically Injured and Arthritic Cartilage |
$55,000 |
|
University of Southern California |
Mark Humayun |
Disease Team Planning |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$50,001 |
|
The Salk Institute for Biological Studies |
Samuel Pfaff |
Disease Team Planning |
Motor neuron diseases: Finding cures through basic, translational, and clinical collaboration |
$54,798 |
|
The J. David Gladstone Institutes |
Deepak Srivastava |
Disease Team Planning |
Pluripotent Stem Cell–Based Therapy for Heart Disease |
$53,972 |
|
ViaCyte, Inc. |
Emmanuel Baetge |
Disease Team Planning |
Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes |
$48,950 |
|
Stanford University |
Thomas Rando |
Disease Team Planning |
Stem Cell Therapy for Muscular Dystrophy |
$52,650 |
|
University of California, San Diego |
Lawrence Goldstein |
Disease Team Planning |
Human Stem Cell Approaches to Alzheimers Disease Therapies |
$55,000 |
|
ViaCyte, Inc. |
Howard Foyt |
Strategic Partnership I |
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes |
$10,075,070 |
|
University of California, Los Angeles |
Irvin Chen |
Disease Team Planning |
Stem Cell Therapy for AIDS- Disease Team Planning |
$52,500 |
|
Bluebird Bio |
David Davidson |
Strategic Partnership I |
A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells [REDACTED] |
$9,363,335 |
|
Buck Institute for Age Research |
Xianmin Zeng |
Disease Team Planning |
Develop a cell replacement therapy for Parkinson's disease using human embryonic stem cells |
$55,000 |
|
University of California, Irvine |
Henry Klassen |
Disease Team Planning |
Stem cells for neuroprotection of photoreceptors in retinitis pigmentosa |
$37,367 |
|
Buck Institute for Age Research |
Mary McEachron |
Major Facilities |
No Title |
$20,500,000 |
|
Ludwig Institute for Cancer Research |
Webster Cavenee |
Disease Team Planning |
Stem Cell-Mediated Oncocidal Therapy of Primary & Metastatic Brain Tumors |
$55,000 |
|
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Major Facilities |
No Title |
$43,000,000 |
|
Children's Hospital of Oakland Research Institute |
Mark Walters |
Disease Team Planning |
CIRM Disease Team Planning Award |
$55,000 |
|
Stanford University |
John Hennessy |
Major Facilities |
No Title |
$43,578,000 |
|
Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Planning |
{REDACTED} Heart Disease Regenerative Medicine Team Planning Award |
$46,886 |
|
University of California, Berkeley |
George Breslauer |
Major Facilities |
No Title |
$20,183,500 |
|
University of California, Irvine |
Leslie Thompson |
Disease Team Planning |
Huntington's Disease Team |
$54,618 |
|
The Parkinson's Institute |
Dennis Steindler |
Research Leadership 10 |
Stem Cell Pathologies in Parkinson’s disease as a key to Regenerative Strategies |
$6,718,471 |
|
University of California, Davis |
Larry Vanderhoef |
Major Facilities |
No Title |
$20,082,400 |
|
University of California, San Francisco |
Tippi MacKenzie |
New Faculty Physician Scientist |
In Utero Embryonic Stem Cell Transplantation to Treat Congenital Anomalies |
$2,661,742 |
|
University of California, Los Angeles |
Yi Sun |
Basic Biology III |
Studying neurotransmission of normal and diseased human ES cell-derived neurons in vivo |
$1,382,400 |
|
University of California, San Francisco |
Katherine Nielsen |
Creativity Awards |
[REDACTED] SEP High School Intern Program |
$143,550 |
|
OncoMed Pharmaceuticals, Inc. |
Timothy Hoey |
Disease Team Therapy Planning I |
[REDACTED]: A New Cancer Therapeutic to Reduce CSC Frequency |
$65,120 |
|
University of California, San Francisco |
Holger Willenbring |
Early Translational III |
Generation of safe and therapeutically effective human induced hepatocyte-like cells |
$1,544,170 |
|
Cedars-Sinai Medical Center |
Robert Baloh |
New Faculty Physician Scientist |
Human iPSC modeling and therapeutics for degenerative peripheral nerve disease |
$3,031,737 |
|
The J. David Gladstone Institutes |
Deepak Srivastava |
Basic Biology III |
Mechanisms of Direct Cardiac Reprogramming |
$1,708,560 |
|
University of California, Davis |
Nancy Lane |
Disease Team Therapy Planning I |
Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis |
$110,000 |
|
The J. David Gladstone Institutes |
Deepak Srivastava |
Early Translational III |
Direct Cardiac Reprogramming for Heart Regeneration |
$6,319,110 |
|
Beckman Research Institute of City of Hope |
Jiing-Kuan Yee |
Basic Biology III |
Use of human iPS cells to study spinal muscular atrophy |
$1,268,868 |
|
Cedars-Sinai Medical Center |
Dan Gazit |
Disease Team Therapy Planning I |
Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$109,743 |
|
Stanford University |
Helen Blau |
Early Translational III |
Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,920 |